Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: A matched-pair pilot study

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Sirolimus, a potent new immunosuppressant, has been anecdotally associated with surgical wound complications. We studied postoperative surgical wound complications in 15 kidney recipients receiving sirolimus, prednisone, and tacrolimus or cyclosporine. (study group) compared with 15 recipients receiving tacrolimus, prednisone, and mycophenolate mofetil who were pair-matched for surgical wound complication risk factors. Surgical wound complications were defined as any complication related to the surgical transplant wound requiring reintervention. Fifty-three percent of the study group and 7% of the control group experienced more than one surgical wound complication (P=0.014), and the relaparotomy incidence was 33% and 7%, respectively. Four graft losses have occurred since the beginning of the study: one chronic rejection and two deaths with function in the study group, and one death with function in the control group. At 1 year, graft survival for study recipients compared with control recipients was 87% and 93%, respectively; patient survival was 93% in both groups. Recipients receiving sirolimus demonstrated a significantly higher surgical wound complication rate, but graft and patient survival were not affected. Peritransplant immunosuppression with sirolimus and steroids warrants careful consideration, particularly in recipients with surgical complication risk factors.

Original languageEnglish (US)
Pages (from-to)426-429
Number of pages4
JournalTransplantation
Volume76
Issue number2
DOIs
StatePublished - Jul 27 2003

Fingerprint

Sirolimus
Kidney Transplantation
Immunosuppression
Tacrolimus
Graft Survival
Prednisone
Mycophenolic Acid
Transplants
Control Groups
Immunosuppressive Agents
Surgical Wound
Cyclosporine
Steroids
Kidney
Survival
Incidence

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

@article{d2f1a66c42e847768cdfd8b51711cd3a,
title = "Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: A matched-pair pilot study",
abstract = "Sirolimus, a potent new immunosuppressant, has been anecdotally associated with surgical wound complications. We studied postoperative surgical wound complications in 15 kidney recipients receiving sirolimus, prednisone, and tacrolimus or cyclosporine. (study group) compared with 15 recipients receiving tacrolimus, prednisone, and mycophenolate mofetil who were pair-matched for surgical wound complication risk factors. Surgical wound complications were defined as any complication related to the surgical transplant wound requiring reintervention. Fifty-three percent of the study group and 7{\%} of the control group experienced more than one surgical wound complication (P=0.014), and the relaparotomy incidence was 33{\%} and 7{\%}, respectively. Four graft losses have occurred since the beginning of the study: one chronic rejection and two deaths with function in the study group, and one death with function in the control group. At 1 year, graft survival for study recipients compared with control recipients was 87{\%} and 93{\%}, respectively; patient survival was 93{\%} in both groups. Recipients receiving sirolimus demonstrated a significantly higher surgical wound complication rate, but graft and patient survival were not affected. Peritransplant immunosuppression with sirolimus and steroids warrants careful consideration, particularly in recipients with surgical complication risk factors.",
author = "Christoph Troppmann and Pierce, {Jonathan L} and Gandhi, {Mehul M} and Gallay, {Brian J} and John McVicar and Perez, {Richard V}",
year = "2003",
month = "7",
day = "27",
doi = "10.1097/01.TP.0000072016.13090.4E",
language = "English (US)",
volume = "76",
pages = "426--429",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation

T2 - A matched-pair pilot study

AU - Troppmann, Christoph

AU - Pierce, Jonathan L

AU - Gandhi, Mehul M

AU - Gallay, Brian J

AU - McVicar, John

AU - Perez, Richard V

PY - 2003/7/27

Y1 - 2003/7/27

N2 - Sirolimus, a potent new immunosuppressant, has been anecdotally associated with surgical wound complications. We studied postoperative surgical wound complications in 15 kidney recipients receiving sirolimus, prednisone, and tacrolimus or cyclosporine. (study group) compared with 15 recipients receiving tacrolimus, prednisone, and mycophenolate mofetil who were pair-matched for surgical wound complication risk factors. Surgical wound complications were defined as any complication related to the surgical transplant wound requiring reintervention. Fifty-three percent of the study group and 7% of the control group experienced more than one surgical wound complication (P=0.014), and the relaparotomy incidence was 33% and 7%, respectively. Four graft losses have occurred since the beginning of the study: one chronic rejection and two deaths with function in the study group, and one death with function in the control group. At 1 year, graft survival for study recipients compared with control recipients was 87% and 93%, respectively; patient survival was 93% in both groups. Recipients receiving sirolimus demonstrated a significantly higher surgical wound complication rate, but graft and patient survival were not affected. Peritransplant immunosuppression with sirolimus and steroids warrants careful consideration, particularly in recipients with surgical complication risk factors.

AB - Sirolimus, a potent new immunosuppressant, has been anecdotally associated with surgical wound complications. We studied postoperative surgical wound complications in 15 kidney recipients receiving sirolimus, prednisone, and tacrolimus or cyclosporine. (study group) compared with 15 recipients receiving tacrolimus, prednisone, and mycophenolate mofetil who were pair-matched for surgical wound complication risk factors. Surgical wound complications were defined as any complication related to the surgical transplant wound requiring reintervention. Fifty-three percent of the study group and 7% of the control group experienced more than one surgical wound complication (P=0.014), and the relaparotomy incidence was 33% and 7%, respectively. Four graft losses have occurred since the beginning of the study: one chronic rejection and two deaths with function in the study group, and one death with function in the control group. At 1 year, graft survival for study recipients compared with control recipients was 87% and 93%, respectively; patient survival was 93% in both groups. Recipients receiving sirolimus demonstrated a significantly higher surgical wound complication rate, but graft and patient survival were not affected. Peritransplant immunosuppression with sirolimus and steroids warrants careful consideration, particularly in recipients with surgical complication risk factors.

UR - http://www.scopus.com/inward/record.url?scp=0041766132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041766132&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000072016.13090.4E

DO - 10.1097/01.TP.0000072016.13090.4E

M3 - Article

C2 - 12883205

AN - SCOPUS:0041766132

VL - 76

SP - 426

EP - 429

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -